{
    "clinical_study": {
        "@rank": "94137", 
        "arm_group": [
            {
                "arm_group_label": "TCM and Western Medicine", 
                "arm_group_type": "Experimental", 
                "description": "TCM and Western Medicine:First Infectious diseases soup recipe,every time a dose,Two times a day;Ribavirin 10-15mg per kg every time Western Medicine\uff1aRibavirin 10-15mg per kg every time"
            }, 
            {
                "arm_group_label": "Western Medicine", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Western Medicine\uff1aRibavirin 10-15mg per kg every time"
            }
        ], 
        "brief_summary": {
            "textblock": "To meet eligibility criteria, this study and informed consent of the syndrome of fever\n      associated with bleeding of infectious diseases, severe patients to carry out multicenter,\n      practical randomized controlled clinical research, to compare the curative effect of western\n      medicine, combining Chinese and western medicine treatment, and security, and pathogenesis\n      of TCM and syndrome, severe immune related factor and syndrome type of traditional Chinese\n      medicine, Chinese medicine prescriptions mechanism research."
        }, 
        "brief_title": "Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Viral Haemorrhagic Fever", 
            "Dengue Fever"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dengue", 
                "Dengue Hemorrhagic Fever", 
                "Fever", 
                "Hemorrhage", 
                "Hemorrhagic Fevers, Viral"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized method: using large sample, central randomized, parallel comparison of Chinese\n      and western medicine and western medicine group."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Viral diseases, such as dengue fever, kidney of hemorrhagic fever, such as xinjiang\n             hemorrhagic fever; Or clinical has fever associated with bleeding as the main\n             performance, and confirmed as the new emergent infectious diseases\n\n        Exclusion Criteria:\n\n          -  Diagnosed with flu, hand, foot and mouth disease, viral hepatitis (except the\n             carrier), liver cirrhosis after hepatitis, AIDS, rabies, encephalitis, polio,\n             measles, German measles, chickenpox, herpes, infectious mononucleosis, infectious\n             atypical pneumonia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973855", 
            "org_study_id": "2012ZX10004301-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "TCM and Western Medicine", 
                "description": "Physical cooling,Hydrocortisone", 
                "intervention_name": "Western Medicine", 
                "intervention_type": "Drug", 
                "other_name": "Ribavirin,"
            }, 
            {
                "arm_group_label": [
                    "TCM and Western Medicine", 
                    "Western Medicine"
                ], 
                "description": "Third Infectious diseases soup recipe", 
                "intervention_name": "TCM  and  Western Medicine", 
                "intervention_type": "Drug", 
                "other_name": "Second Infectious diseases soup recipe and Ribavirin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "contact": {
                "email": "xurongfang@vip.sina.com", 
                "last_name": "Xu R Fang", 
                "phone": "13008415052"
            }, 
            "facility": {
                "address": {
                    "city": "XiAn", 
                    "country": "China", 
                    "state": "Shanxi", 
                    "zip": "710000"
                }, 
                "name": "Xi 'an eighth people's hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research", 
        "overall_contact": {
            "email": "Gz8htxh@126.com", 
            "last_name": "Tan X Hua", 
            "phone": "13500039656"
        }, 
        "overall_official": {
            "affiliation": "Guangzhou 8th hospitol", 
            "last_name": "Tan X Hua", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Mortality", 
            "safety_issue": "Yes", 
            "time_frame": "Anytime  of the clinical  trail  from 2011.1.1 to 2015.12.30"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973855"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Guangzhou 8th People's Hospital", 
            "investigator_full_name": "Xinghua Tan", 
            "investigator_title": "Director of Department of infection area", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "With adverse events as the calculation basis", 
            "measure": "Safety outcome", 
            "safety_issue": "Yes", 
            "time_frame": "From 2012.1 to 2015.12"
        }, 
        "source": "Guangzhou 8th People's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangzhou 8th People's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}